Cohen E, Harrington K, Le Tourneau C, et al. Pembrolizumab (pembro) vs standard of care (SOC) for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): Phase 3 KEYNOTE-040 trial. ESMO 2017 Congress; abstract LBA45_PR.
Immuuntherapie ook in de echte wereld succesvol bij gevorderd merkelcelcarcinoom
dec 2020 | Dermato-oncologie, Immuuntherapie